Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BIEI GET IN EARLY BIG PHARMA COMING READ PR
BIEI GET IN EARLY BIG PHARMA COMING READ PR
BIEI FLOAT LOCKED BIG PHARMA COMING SOON LAST CHANCE
BIEI READY TO GO BIG PHARMA APPROACHING RUMOUR BUYOUT
BIG PHARMA LOOKING AT BIEI JUST ABOUT TO GO NEWS IMMINENT
TWO OF THE BIGGEST PHARMA CO. IN WORLD WOULD LIKE TO SPEAK TO BIEI READ PR =MONEY HUGE MONEY PRICE TARGET 10.00
BIEI BIEI ARE WE LOADED YET
BIEI BIEI ARE WE LOADED YET
BIEI FLOAT LOCKED JUST WAITING FOR LETTER OF INTENT ANY TIME NOW
BIEI FLOAT LOCKED JUST WAITING FOR LETTER OF INTENT ANY TIME NOW
MONEY MAKERS KEEPING BIEI QUIET BE SMARTER
TWO OF THE BIGGEST PHARMA COMPANIES WATCHING BIEI THIS IS HUGE
TWO OF THE BIGGEST PHARMA COMPANIES WATCHING BIEI THIS IS HUGE
DNRG HOPE YOU GOT IN
BIEI EASY NICKEL HERE
BIEI 200 PERCENT IN THREE DAYS WHEN NEWS HITS WATCH OUT DON T SAY I DIDNT TELL YOU BUY BUY BUY
BIEI 200 PERCENT IN THREE DAYS WHEN NEWS HITS WATCH OUT DON T SAY I DIDNT TELL YOU BUY BUY BUY
DNRG ON THE MOVE
DNRG GOING NOW
BIEI BIEI MANY PENNIES TO COME
BIEI BIEI MONSTER READ PR
BIEI BIEI IF YOU DIDN T BUY IT IN THE LAST FEW DAYS LIKE I TOLD YOU TO TOMORROW WILL BE YOUR LAST CHANCE MULTI DOLLAR STOCK LOW FLOAT AND LOTS TO OFFER BUY BUY BUY
BIEI BIEI WERE YOU PEOPLE NOT LISTENING THIS IS EASY 10 BUCKS
BIEI BIEI WERE YOU PEOPLE NOT LISTENING THIS IS EASY 10 BUCKS
Premier Biomedical Inc. Fact Sheet.
? Premier Biomedical (PBI) is a publicly traded research-based company that intends to
discover and develop medical treatments targeting the treatment of heretofore incurable
and/or hard-to-cure diseases.
? The Company’s proprietary Sequential Dialysis Technique is a methodology that physically
removes the pathophysiologic basis of the disease, eliminating it without dangerous side
effects.
o Superior to current treatments which eliminate the presence of most illnesses but
often with catastrophic or even fatal side effects.
o Subtractive therapy (removal of harmful molecules) reduces risks associated with
conventional “Additive” therapy (adding chemicals to the body).
o Targets Cancer, Leukemia, Cockayne Syndrome, Neurofibromatosis, Fibromyalgia,
Multiple Sclerosis, and Atherosclerosis – collectively over $700 billion market
opportunity.
? Developed a proprietary patented drug candidate, Feldetrex™ as a potential treatment for
Fibromyalgia, neuropathic pain, and chemical addiction.
o Expected to deliver significant relief to patients, while presenting fewer side effects
than other alternate medications.
o The annual market size of all proposed market segments for Feldetrex™ is over $20
billion.
o The company strategy is to use the sales of Feldetrex™ to provide short term
revenue and to fund technology.
? Penn Biomedical Group (PBG) study analyzed potential market for Feldetrex versus
entrenched competition, Lyrica and Cymbalta, whose sales exceed $10B currently.
? The Company has established two outstanding research partnerships with the University of
Texas, El Paso (UTEP) and the Department of Defense
o Leverage the substantial infrastructure and resourced capacity of these
organizations to perform experimentation and to engage in product development in
an inexpensive and efficient manner.
o UTEP contractually owns 10% of PBI profits associated with their direct participation
programs. The DoD contractually can receive medications at PBI cost.
o Superior results in animal testing of proprietary immunotherapy cancer antibody
treatments targeting cancer antigens CTLA-4, PD-1, and BTLA protein activities.
? A second PBG study examined anti-cancer drug potential sales, indicating a potential
revenue of $1.9 B.
? In order to establish short term revenue to finance on-going research, the Company has
initiated efforts to establish Joint Ventures with established pharmaceutical firms in South
America & Asia to develop, manufacture and distribute Premier Biomedical’s treatments and
drugs. Press releases announcing these joint ventures will be issued shortly.
? An outside healthcare market advisor in Brazil forecasted potential sales of PBI products in
South America of $400M per year by 2020.
BIEI BIEI NEXT PENNY STOCK OF 2016 BUY BUY BUY BYE BYE
BIEI BIEI NEXT PENNY STOCK OF 2016 BUY BUY BUY BYE BYE
BIEI BIEI NEXT PENNY STOCK OF 2016 BUY BUY BUY BYE BYE
PPCH PPCH HERE WE GO
BIEI COULD BE A BUYOUT
BIEI BIEI TODAY THE TRAIN LEAVES
BIEI THE TRAIN IS READY TO LEAVE THE STAION BIEI
BIEI DONT WAIT ANY LONGER RESULTS WILL COME AT ANY TIME
BIEI DONT WAIT ANY LONGER RESULTS WILL COME AT ANY TIME
BIEI TRAIN ABOUT TO LEAVE
BIEI IS READY GET IN FOR THE RIDE
LETS DUMP PPCH AND GET INTO BIEI BETTER
Premier Biomedical/UTEP Demonstrate New Anti-Cancer Immunotherapy Drug; May Compete Against Best of Big Pharma Drugs
El Paso, TX -- (ReleaseWire) -- 04/25/2016 -- Premier Biomedical, Inc. (OTCQB:BIEI) revealed the results of its latest cancer immunotherapy work being conducted by its research partner, UTEP, at the recent American Association for Cancer Research (AACR) Conference, in New Orleans. The patent-pending anti-cancer antibody is intended to compete in the immunotherapy segment of the $100 plus billion cancer treatment market, with drugs like Yervoy® by Bristol Meyers Squibb who is projecting sales of $14 billion by 2018.
William A. Hartman, President and CEO of Premier Biomedical, stated, "This new drug has shown to be effective in blocking 98.8% of CTLA-4 breast cancer-causing antigens in laboratory tests, compared to 36% for the drug we presented in 2014. In our mouse testing, both of these antibodies demonstrated immunity to re-injections of breast cancer after treatment."
Hartman indicated that the company plans comparison tests of other available immunotherapy drugs to verify the belief that this new antibody may be the most effective anti-breast cancer drug in the world. "We have also developed antibodies against other cancer-causing antigens and plan animal tests to compare them to other available treatments in the near future," he said.
Contact William A. Ha
Premier Biomedical/UTEP Demonstrate New Anti-Cancer Immunotherapy Drug; May Compete Against Best of Big Pharma Drugs
BIEI BIEI IT WONT LAST THE MONEY MAKERS CANT HOLD IT FOR TO MUCH LONGER NEWS SHOULD HIT ANY TIME WHEN IT DOES LOOK OUT